REQUITE: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality-of-life in cancer survivors - REQUITE

MAASTRO clinic0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年4月23日

试验速览

暂无简介。

•* Confirmed diagnosis of the specified tumour types, for lung cancer confirmation either by histology or based on radiological findings
•* Patients suitable for radical radiotherapy or brachytherapy for prostate cancer; including post-prostatectomy patients
•* Patients suitable for radical radiotherapy, sequential or concurrent chemoradiotherapy or stereotactic body radiation therapy for lung cancer
•* No other malignancy in the last 5 years prior to treatment for the specified tumour types except basal cell or squamous cell carcinoma of the skin
•* No evidence of distant metastases
•* Patients able to provide a venous blood sample
•* Willingness and ability to comply with scheduled visits, treatment plans and available for follow up within country of origin
•* Greater than 18 years of age; no upper age limit
•* The capacity to understand the patient information sheet and the ability to provide written informed consent

•* Patients with metastatic disease
•* Prior irradiation at the same site
•* Planned use of protons
•* High Intensity Focal Ultrasound (HIFU)
•* Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires
•* Limited life expectancy due to co-morbidity
•Pregnant patients
•* Patients with known HIV infection/infectious hepatitis

发起方